Ordaōs Bio and Nonexomics LLC have established a proof-of-concept research collaboration to create customized mini-proteins.

Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer.

Avicanna Inc. has expanded its research in the field of epilepsy through a new collaboration with the University of Toronto to explore the efficacy of Avicanna's proprietary formulations in preclinical models of epilepsy.

Coave Therapeutics SA has entered into a collaboration with the Institute of Neurodegenerative Diseases (IMN), a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS), to develop gene therapy programs targeting protein degradation in neurodegenerative disorders.

Nanotics LLC has established a research collaboration with Mass General Cancer Center (MGCC), a program of Massachusetts General Hospital (MGH), to develop Nanots that target the soluble forms of tumor necrosis factor (TNF) receptors (sTNF-Rs).